Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT

Completed · Not applicable

Conditions studied: Central Line Associated Bloodstream Infections (CLABSI), Bone Marrow Transplant

In brief

The purpose of this study is to see if applying parafilm as an external barrier on the central line in children having a bone marrow transplant helps to prevent central line associated bloodstream infection(s) and also to assess the ease of use of parafilm.

Key facts

Study ID

NCT02575079

Run by

Emory University

People needed

119

Starts

2015-03-01

Expected to finish

2018-03-29

Last updated by the study team

2019-06-25

Who can join

Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must be between the age of 0 and 21 years at the time of enrollment
• Must be undergoing allogeneic or autologous HCT for a malignant or non-malignant disorder
• Must have or be scheduled to have a tunneled CVC

You may not qualify if…

• Patients undergoing other interventions to prevent CLABSI (e.g. Children's Oncology Group (COG) study ACCL1034 with Chlorhexidine Gluconate (CHG); antimicrobial lock therapy, etc.)
• Patients who only have a port

Where it is running

• Children's Healthcare of Atlanta — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.